Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results

Celldex Therapeutics (NASDAQ:CLDX) released its earnings results on Monday. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13), Zacks reports. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.

Celldex Therapeutics Trading Down 1.0%

CLDX stock traded down $0.23 during midday trading on Monday, hitting $22.67. The stock had a trading volume of 1,383,948 shares, compared to its average volume of 1,018,084. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $29.05. The stock has a 50-day simple moving average of $25.42 and a 200 day simple moving average of $22.75. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -7.53 and a beta of 1.36.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the second quarter valued at $125,000. Tower Research Capital LLC TRC raised its holdings in shares of Celldex Therapeutics by 289.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 5,387 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Celldex Therapeutics during the 2nd quarter worth about $347,000. Finally, Jump Financial LLC grew its holdings in Celldex Therapeutics by 53.3% during the 2nd quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock worth $600,000 after acquiring an additional 10,255 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CLDX shares. HC Wainwright dropped their price target on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Barclays initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 13th. They set an “underweight” rating and a $25.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. Finally, Mizuho assumed coverage on Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $44.20.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.